{"url_path":"/sec/pbm/10-k/2026/item-16j","section_key":"item-16j","section_title":"Item 16J INSIDER TRADING POLICIES","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1985062/0001213900-26-070607-index.html","accession_number":"0001213900-26-070607","cik":"0001985062","ticker":"PBM","issuer_name":"PSYENCE BIOMEDICAL LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1985062/0001213900-26-070607-index.html","primary_entity_key":"0001985062","primary_entity_name":"PSYENCE BIOMEDICAL LTD."},"word_count":65,"has_tables":true,"body_markdown":"** **\n\nITEM 16J. INSIDER TRADING POLICIES\n\n \n\nOur Board has adopted insider trading policies\nand procedures governing the purchase, sale, and other dispositions of our securities by directors, senior management, and employees that\nare reasonably designed to promote compliance with applicable insider trading laws, rules, and regulations, and any listing standards\napplicable to us. A copy of the insider trading policy is filed herewith as Exhibit 11.2."}